BioSpace News Archive

Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), a global commercial manufacturer of high quality cannabinoid-based ingredients, formulations and products, is pleased to report its financial results for the third quarter of its fiscal year 2020, ended December 31, 2019. The financial statements and Management’s Discussion & Analysis are available under the Company’s profile at www.SEDAR.com.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on February 28, 2020 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to fourteen individuals hired by Sarepta in February 2020.

Accolade, Inc. (“Accolade”), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, today announced it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed initial public offering of shares of its common stock

AbbVie announced the VIALE-C trial of venetoclax in combination with low-dose cytarabine versus LDAC in combination with placebo did not meet its primary endpoint of statistically significant improvement of overall survival for patients with acute myeloid leukemia who are ineligible for intensive chemotherapy at the time of the planned analysis.

DENTSPLY SIRONA Inc., The Dental Solutions Company™, announced that its Board of Directors declared a quarterly cash dividend of $0.10 per share of common stock, an indicated annual rate of $0.40 per share.

The sudden outbreak of the COVID-19 virus made the 2020 Chinese New Year one of the most unusual ever.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Tuesday March 3, 2020 at 8:00 AM ET to discuss results for the fourth quarter and year-end 2019 and provide a business outlook for 2020

KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today provided an update on the KP415 NDA and reported its financial results for the fourth quarter and full-year ended December 31, 2019.

Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive officer of Morphic Therapeutic, is scheduled to present at the 40th Annual Cowen Health Care Conference at 8:00 AM ET on Wednesday, March 4, 2020

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its fourth quarter and full year 2019 financial results will be released on Wednesday, March 4, 2020 before the U.S. financial markets open.